Farnesyltransferase inhibitor improved survival following endotoxin challenge in mice.
暂无分享,去创建一个
R. Tompkins | M. Kaneki | M. Fukaya | A. Fischman | E. Carter | Yong-ming Yu | Wen Yang | S. Shinozaki | Y. Inoue | Shohei Shinozaki | Yong‐ming Yu | Makiko Fukaya
[1] V. Sukhatme,et al. Statin‐induced muscle damage and atrogin‐1 induction is the result of a geranylgeranylation defect , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[2] D. Green,et al. Caspase-7 deficiency protects from endotoxin-induced lymphocyte apoptosis and improves survival. , 2009, Blood.
[3] T. Tsuji,et al. Therapeutic effects of erythropoietin in murine models of endotoxin shock* , 2009, Critical care medicine.
[4] A. Stalenhoef,et al. Effects of ubiquinone (coenzyme Q10) on myopathy in statin users , 2008, Current opinion in lipidology.
[5] Ji-xiang Zhang,et al. A Role of Cell Apoptosis in Lipopolysaccharide (LPS)-induced Nonlethal Liver Injury in d-galactosamine (d-GalN)-sensitized Rats , 2008, Digestive Diseases and Sciences.
[6] H. Redmond,et al. Statin (cerivastatin) protects mice against sepsis-related death via reduced proinflammatory cytokines and enhanced bacterial clearance. , 2008, Surgical infections.
[7] M. Falagas,et al. Statins for infection and sepsis: a systematic review of the clinical evidence. , 2008, The Journal of antimicrobial chemotherapy.
[8] D. Thickett,et al. Statins and sepsis. , 2008, British journal of anaesthesia.
[9] C. Iadecola,et al. Farnesyl transferase inhibitors induce neuroprotection by inhibiting Ha‐Ras signalling pathway , 2007, The European journal of neuroscience.
[10] G. Arteel,et al. Early growth response-1 contributes to galactosamine/lipopolysaccharide-induced acute liver injury in mice. , 2007, American journal of physiology. Gastrointestinal and liver physiology.
[11] Wei Wei,et al. Melatonin attenuates lipopolysaccharide (LPS)-induced apoptotic liver damage in D-galactosamine-sensitized mice. , 2007, Toxicology.
[12] M. Kaneki,et al. Farnesyltransferase Inhibitor, Manumycin A, Prevents Atherosclerosis Development and Reduces Oxidative Stress in Apolipoprotein E-Deficient Mice , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[13] Kenji Suzuki,et al. An inhibitor of c-Jun NH2-terminal kinase, SP600125, protects mice from D-galactosamine/lipopolysaccharide-induced hepatic failure by modulating BH3-only proteins. , 2007, Life sciences.
[14] R. Talbert,et al. Effectiveness of Statins in Reducing the Rate of Severe Sepsis: A Retrospective Evaluation , 2007, Pharmacotherapy.
[15] C. Trautwein,et al. The role of JNK2 in toxic liver injury. , 2006, Journal of Hepatology.
[16] R. Hotchkiss,et al. Apoptosis and caspases regulate death and inflammation in sepsis , 2006, Nature Reviews Immunology.
[17] A. Hoes,et al. Statin treatment and reduced risk of pneumonia in patients with diabetes , 2006, Thorax.
[18] G. Spagnuolo,et al. Inhibition of Ras/ERK1/2 signaling protects against postischemic renal injury. , 2006, American journal of physiology. Renal physiology.
[19] Ping Li,et al. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis , 2006, The Lancet.
[20] A. Anzueto,et al. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia , 2005, Respiratory research.
[21] C. Weber,et al. Statin Treatment After Onset of Sepsis in a Murine Model Improves Survival , 2005, Circulation.
[22] M. Jeschke,et al. Insulin prevents liver damage and preserves liver function in lipopolysaccharide-induced endotoxemic rats. , 2005, Journal of hepatology.
[23] M. Kaneki,et al. Inducible Nitric-oxide Synthase and NO Donor Induce Insulin Receptor Substrate-1 Degradation in Skeletal Muscle Cells* , 2005, Journal of Biological Chemistry.
[24] J. Carcillo,et al. Prolonged Lymphopenia, Lymphoid Depletion, and Hypoprolactinemia in Children with Nosocomial Sepsis and Multiple Organ Failure1 , 2005, The Journal of Immunology.
[25] Eriko Tokunaga,et al. S-Nitrosylation-dependent Inactivation of Akt/Protein Kinase B in Insulin Resistance* , 2005, Journal of Biological Chemistry.
[26] V. Novack,et al. Prior Statin Therapy Is Associated With a Decreased Rate of Severe Sepsis , 2004, Circulation.
[27] C. Weber,et al. HMG-CoA Reductase Inhibitor Simvastatin Profoundly Improves Survival in a Murine Model of Sepsis , 2004, Circulation.
[28] R. Hotchkiss,et al. INCREASED LYMPHOID TISSUE APOPTOSIS IN BABOONS WITH BACTEREMIC SHOCK , 2004, Shock.
[29] F. Mach,et al. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. , 2003, Autoimmunity reviews.
[30] Robert Kleemann,et al. Rosuvastatin Reduces Atherosclerosis Development Beyond and Independent of Its Plasma Cholesterol–Lowering Effect in APOE*3-Leiden Transgenic Mice: Evidence for Antiinflammatory Effects of Rosuvastatin , 2003, Circulation.
[31] V. Gahtan,et al. Noncholesterol-Lowering Effects of Statins , 2003, Vascular and endovascular surgery.
[32] Anat Biegon,et al. The Ras Inhibitor S-Trans, Trans-Farnesylthiosalicylic Acid Exerts Long-Lasting Neuroprotection in a Mouse Closed Head Injury Model , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[33] N. Hagiwara,et al. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. , 2002, British journal of clinical pharmacology.
[34] J. Liao,et al. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[35] U. Laufs,et al. HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species , 2001, Hypertension.
[36] R. Hotchkiss,et al. Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans1 , 2001, The Journal of Immunology.
[37] A. Iguchi,et al. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. , 2001, Atherosclerosis.
[38] T. Takamura,et al. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. , 2000, The Journal of pharmacology and experimental therapeutics.
[39] J. Deanfield,et al. Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. , 2000, Journal of the American College of Cardiology.
[40] J. Raymond,et al. Expression of a Dominant‐Negative Mutant of p21ras Inhibits Induction of Nitric Oxide Synthase and Activation of Nuclear Factor‐κB in Primary Astrocytes , 2000 .
[41] D. Remick,et al. Endotoxin, sepsis, and the primrose path. , 1999, Shock.
[42] R. Hotchkiss,et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. , 1999, Critical care medicine.
[43] H. Jaeschke,et al. Activation of caspase 3 (CPP32)-like proteases is essential for TNF-alpha-induced hepatic parenchymal cell apoptosis and neutrophil-mediated necrosis in a murine endotoxin shock model. , 1998, Journal of immunology.
[44] C. Der,et al. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? , 1997, Biochimica et biophysica acta.
[45] K. Feingold,et al. Endotoxin, tumor necrosis factor, and interleukin-1 decrease hepatic squalene synthase activity, protein, and mRNA levels in Syrian hamsters. , 1997, Journal of lipid research.
[46] C. Natanson,et al. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. , 1997, Critical care medicine.
[47] S. Opal,et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.
[48] K. Feingold,et al. Discordant regulation of proteins of cholesterol metabolism during the acute phase response. , 1995, Journal of lipid research.
[49] D. Pittet,et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. , 1995, JAMA.
[50] J. Taylor,et al. Effect of endotoxin on cholesterol biosynthesis and distribution in serum lipoproteins in Syrian hamsters. , 1993, Journal of lipid research.
[51] S. Grundy,et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. , 2004, Journal of the American College of Cardiology.